Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human
-
Publication number: 20250136938Abstract: Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: December 30, 2024Publication date: May 1, 2025Applicant: The United States of America,as represented by the Secretary, Department of Health and Human ServicInventors: Gal Cafri, Steven A. Rosenberg
-
Publication number: 20250134897Abstract: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a compound of Formula (I), as well as a pharmaceutical composition containing a hyperpolarized compound of Formula (I). Also disclosed is a method of diagnosing or monitoring a patient suffering from cancer, the method including administering a pharmaceutical composition comprising an effective amount of a hyperpolarized ketoglutarate compound or a pharmaceutically acceptable salt thereof, and measuring the hyperpolarization of a compound of interest in the patient. Further disclosed is a method of preparing hyperpolarized ketoglutarate compounds for use in the above methods.Type: ApplicationFiled: January 26, 2023Publication date: May 1, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rolf E. SWENSON, Jessica H. ETTEDGUI-BENJAMINI, Venkatareddy SABBASANI, Deepak SAIL, Kazutoshi YAMAMOTO, Murali K. CHERUKURI
-
Publication number: 20250134907Abstract: Disclosed is a compound of formula (I), in which R1, R2, R3, R4, R5, X1, X2, X3, X4, and X5 are described herein. The small molecule compounds of formula (I) activate the functional activity of relaxin family peptide receptor 2 (RXFP2), thereby providing therapeutic treatments for a variety of disorders, such as a bone disorder, hypogonadism, cryptorchidism, polycystic ovary syndrome, cancer, infertility, or an ocular wound.Type: ApplicationFiled: January 31, 2023Publication date: May 1, 2025Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Florida International University Board of TrusteesInventors: Juan J. Marugan, Noel T. Southall, Marc Ferrer, Mark J. Henderson, Kenneth J. Wilson, Alexander I. Agoulnik, Courtney B. Myhr, Maria Esteban-Lopez, Elena Barnaeva, Xin Hu, Wenjuan Ye, Irina Agoulnik
-
Publication number: 20250127887Abstract: The present disclosure relates to a vaccine comprising an amphiphile having the formula S-[B]-[U]-H and at least one peptide antigen conjugate having the formula selected from [S]-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-[S], wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.Type: ApplicationFiled: February 16, 2022Publication date: April 24, 2025Applicants: Barinthus Biotherapeutics North America, Inc., The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Geoffrey M. Lynn, Sarah R. Nichols, Vincent L. Coble, Andrew S. Ishizuka, Hugh Clarke Welles, Robert N. Goddu, Christopher Martin O’Brien Garliss, Ramiro Andrei Ramirez-Valdez
-
Publication number: 20250130234Abstract: The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays. Also provided are non-parametric methods for analyzing data from RT-CETSA and other biological target engagement assays.Type: ApplicationFiled: December 21, 2022Publication date: April 24, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Michael H. Ronzetti, Mark J. Henderson, Tino W. Sanchez, Samuel G. Michael, Ty C. Voss, Bolormaa Baljinnyam, Anton Simeonov
-
Patent number: 12281060Abstract: Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.Type: GrantFiled: April 2, 2020Date of Patent: April 22, 2025Assignees: The University of Chicago, The United States of America, as Represented by the Secretary, Department of Health and Human Services, President and Fellows of Harvard College, IIT Research Institute, Beth Israel Deaconess Medical Center Inc.Inventors: Julian Solway, Nickolai Dulin, Diane Luci, David Maloney, Chan Young Park, Jeffrey Fredberg, David McCormick, Ramaswamy Krishnan
-
Patent number: 12281336Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.Type: GrantFiled: May 27, 2024Date of Patent: April 22, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
-
Publication number: 20250122473Abstract: Disclosed are methods of preparing thymic emigrant cells in vitro, isolated or purified thymic emigrant cells prepared by the methods, and pharmaceutical compositions comprising the same. Further disclosed are methods of treating or preventing a condition in a mammal comprising administering the thymic emigrant cells or pharmaceutical compositions comprising the same to the mammal.Type: ApplicationFiled: December 18, 2024Publication date: April 17, 2025Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Raul E. Vizcardo, Nicholas D. Klemen, Nicholas P. Restifo
-
Patent number: 12275786Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: August 4, 2022Date of Patent: April 15, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Patent number: 12275758Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: GrantFiled: January 10, 2024Date of Patent: April 15, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Patent number: 12268737Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: April 26, 2024Date of Patent: April 8, 2025Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Patent number: 12269872Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: GrantFiled: May 4, 2020Date of Patent: April 8, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
-
Patent number: 12270738Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.Type: GrantFiled: April 8, 2022Date of Patent: April 8, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
-
Patent number: 12268700Abstract: Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.Type: GrantFiled: March 25, 2019Date of Patent: April 8, 2025Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of ConnecticutInventors: Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stewart K. Richardson
-
Patent number: 12270881Abstract: Kinetic monitoring of in vivo metabolism of labelled tracers is based on singular value decomposition or Tucker Decomposition of magnetic resonance spectral image data. Data decomposition is used in conjunction with rank reduction to improve signal-to-noise ratio. Rank reduction can be applied in one or more of a spectral, spatial, or temporal dimension. Rank is generally reduced based on a number of expected analytes/metabolites or fit of measured data to a model.Type: GrantFiled: January 14, 2022Date of Patent: April 8, 2025Assignee: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Jeffrey R. Brender, James B. Mitchell, Kazutoshi Yamamoto, Shun Kishimoto, Jeeva P. Munasinghe, Hellmut Merkle, Murali K. Cherukuri
-
Publication number: 20250109175Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.Type: ApplicationFiled: December 5, 2024Publication date: April 3, 2025Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, New York UniversityInventors: Genoveffa Franchini, Timothy Cardozo, Manuel Becerra-Flores, Isabela Silva de Castro, Giacomo Gorini, Massimiliano Bissa
-
Publication number: 20250090658Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.Type: ApplicationFiled: December 5, 2024Publication date: March 20, 2025Applicants: Oxford University Innovation Limited, The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
-
Publication number: 20250095390Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.Type: ApplicationFiled: May 13, 2024Publication date: March 20, 2025Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
-
Patent number: 12251432Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.Type: GrantFiled: October 21, 2020Date of Patent: March 18, 2025Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Sara Lustigman, Thomas B. Nutman, Sasisekhar Bennuru
-
Patent number: 12239654Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: GrantFiled: April 21, 2017Date of Patent: March 4, 2025Assignees: Astrocyte Pharmaceuticals, Inc., Board of Regents, The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: William S. Korinek, James D. Lechleiter, Theodore E. Liston, Kenneth A. Jacobson